Placebo MDI HFA

DRUG2 trials

Sponsors

AstraZeneca

Conditions

AsthmaCOPD (Chronic Obstructive Pulmonary Disease)

Phase 3

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

CompletedNCT06075095

AstraZenecaCOPD (Chronic Obstructive Pulmonary Disease)

Start: 2024-01-11End: 2025-08-12Updated: 2025-08-27

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

CompletedNCT06502366

AstraZenecaAsthma

Start: 2024-07-22End: 2026-04-17Updated: 2026-09-08